Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cetuximab in the treatment of patients with colorectal cancer.

Expert opinion on biological therapy - 1 Jul 2011

Garrett Christopher R, Eng Cathy

Abstract excerpt

INTRODUCTION: Cetuximab is a chimeric mAb with avidity for the EGFR higher than that of the natural ligands of the receptor. Preclinical studies showed that cetuximab demonstrated synergy with topoisomerase I inhibitors in the treatment of human colorectal cancer (CRC) cell lines in vivo. Subsequent clinical trials have shown that cetuximab can reverse resistance to topoisomerase I inhibitors in addition to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to Antibodies, Monoclonal, Humanized
Share to Camptothecin

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cetuximab

Share to Evidence-Based Medicine

Share to Irinotecan

Share to Precision Medicine

Share to ras Proteins

Source

Identifiers

PMID: 21557708
DOI: 10.1517/14712598.2011.582464

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cetuximab in the treatment of patients with colorectal cancer.PMID 21557708Read ↗

Impact of cetuximab in current treatment of metastatic colorectal cancer.Semantic proximity Read ↗

How do we optimally use cetuximab in first-line treatment for metastatic colorectal cancer?Semantic proximity Read ↗

Cetuximab in metastatic colorectal cancer.Semantic proximity Read ↗

Cetuximab: a guide to its use in combination with FOLFIRI in the first-line treatment of metastatic colorectal cancer in the USA.Semantic proximity Read ↗

First-Line Cetuximab Monotherapy in KRAS/NRAS/BRAF Mutation-Negative Colorectal Cancer Patients.Semantic proximity Read ↗

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.Semantic proximity Read ↗

Role of cetuximab in first-line treatment of metastatic colorectal cancer.Semantic proximity Read ↗

Standard chemotherapy with cetuximab for treatment of colorectal cancer.Semantic proximity Read ↗

Targeted Therapy for Colorectal Cancer.Semantic proximity Read ↗

Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.Semantic proximity Read ↗

Targeting the epidermal growth factor receptor in metastatic colorectal cancer.Semantic proximity Read ↗

Targeted therapy in advanced colorectal cancer: more data, more questions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.